WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD), has been named to Training magazine’s 2020 Training Top 125 list, recognizing organizations that excel at employee training and development.
“PPD empowers our greatest asset, our talented and committed employees, to achieve a culture of high performance that enables exceptional service delivery for our pharmaceutical and biotech customers,” said Jay Dixon, senior vice president of quality and enterprise learning at PPD. “Our strategic approach focuses on providing learning and development programs to foster a top-tier learning culture, exemplified by employee growth and achievement.”
2020 marks the ninth consecutive year PPD has been named to the magazine’s list of top 125 businesses. The Training Top 125 list is decided by assessing a range of qualitative and quantitative factors, including investment in employee development, the scope of development programs, how closely such development efforts are linked to business goals and objectives, and the results they achieve.
Alisha Talley, principal learning specialist at PPD, also was honored by Training magazine as a winner of the Emerging Training Leaders Awards, which recognize training professionals with two to 10 years of industry experience whose leadership skills, business savvy and training instincts are driving change and innovation in their organizations.
PPD and Talley were recognized Feb. 24 during the Training 2020 Conference & Expo at Disney’s Coronado Springs Resort in Orlando, Florida.
“The 2020 Training Top 125 winners demonstrate the magic that happens when organizations tie training to specific, measurable strategic goals, leading to the behavior change, business impact and employee engagement that drive success,” said Lorri Freifeld, editor-in-chief of Training magazine. “We salute these best-in-class organizations for their ardent dedication to continuous employee learning and development and their investment in innovative ways to deliver on their commitment.”
About PPD
PPD (Nasdaq:PPD), is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 23,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.
This news release contains forward-looking statements. These statements often include words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “targets,” “projections,” “should,” “could,” “would,” “may,” “might,” “will,” and other similar expressions. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include: the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; any failure of our backlog to predict or convert into future revenue; the fact that our customers can terminate, delay or reduce the scope of our contracts with them upon short notice or with no notice; the impact of industry, customer and therapeutic area concentration; our ability to accurately price our contracts and manage our costs associated with performance of such contracts; any failures in our information and communication systems, impacting us or our customers, clinical trial participants or employees; any failure to perform services in accordance with contractual requirements, regulatory standards and ethical standards; our ability to recruit, retain and motivate key personnel; our ability to attract suitable investigators or enroll a sufficient number of patients for our customers’ clinical trials; any failure by us to comply with numerous privacy laws; our dependence on third parties for critical goods and support services; our dependence on our technology network, and the impact from upgrades to the network; any violation of laws, including laws governing the conduct of clinical trials or other biopharmaceutical research, and anti-corruption laws; competition between our existing and potential customers and the potential negative impact on our business; our management of business restructuring transactions and the integration of acquisitions; risks related to the drug development services industry that could result in potential liability; any failure of our insurance to cover the potential liabilities associated with the operation of our business and provision of services; our use of biological and hazardous materials, which could result in liability; international or U.S. economic, currency, political and other risks; economic conditions and regulatory changes from the United Kingdom’s proposed exit from the European Union; any inability to adequately protect our intellectual property or the security of our systems and the data stored therein; consolidation amongst our customers, and the potential for rationalization of the combined drug development pipeline, resulting in fewer products in clinical development; any patent or other intellectual property litigation we might be involved in; changes in tax laws, or interpretations of existing tax laws; our investments in third parties; the substantial value of our goodwill and intangible assets, which we might not fully realize, resulting in impairment losses; difficult and volatile conditions in the capital and credit markets and in the overall economy; risks related to our indebtedness; the significant influence of certain significant stockholders over us; and other factors. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
